WIXOM, MI (
) -- Consider a run-up trade in a biotech stock after it raises money. A recent example: Last January,
sold 6.3 million shares at a 9% discount to its market price at the time. Over the next two months -- and ahead of results from a clinical trial of its lead antibiotic -- Trius shares ran up more than 50%.
I'm giving this strategy another go with
(RMTI - Get Report)
, marketer of dialysis related products. On Monday, Rockwell closed a $40 million stock offering, which should provide the company with enough cash to fund operations into 2014. Rockwell spends a lot of money and its balance sheet has been weak, so this latest offering -- priced at a small discount to market price -- should alleviate investors concerns about the company's cash and attract new buyers to the stock.
Rockwell's looming catalyst is data from two phase III studies of an experimental soluble iron solution added to the dialysis fluid of kidney dialysis patients in order to prevent iron deficiency and anemia.
The pivotal studies are evaluating the ability of Rockwell's SFP to maintain target hemoglobin levels in kidney dialysis patients. Results from the first study are expected in July, the second in October.
I expect Rockwell shares to rise significantly if the July study results come back positive. Remember
(KERX - Get Report)
shot up from $3 to $10 based on positive results from a phase III study of its iron-based phosphate binder in kidney dialysis. Rockwell's SFP is a potential Keryx competitor.
Of course, I trade the run-ups into biotech catalysts and rarely, if ever, risk my capital on the actual event. With Rockwell's balance sheet strengthened, I'm betting on investors running the stock up into the July release of SFP clinical trial results. I'll be exiting my position before July.
Messier is long Rockwell Medical.